Fig. 3
From: A novel dephosphorylation targeting chimera selectively promoting tau removal in tauopathies
DEPTAC reduces phosphorylated and total tau in the hippocampus of Tau368 mice. a The expression of hTau-N368 was controlled by the NSE promoter and a tet-on system. b, c Prominent hTau-N368 expression was detected by immunohistochemistry (b) and Western blotting (c) in the dorsal hippocampus of the dox-, but not normal water (NW)-drinking group. d Experimental procedures for drugs administration. DEPTAC or vehicle was administrated for once or a consecutive month during dox on. e DEPTAC for once reduced phosphorylated and total tau prominently at 5 mM and 12–72 h of post intra-cerebroventricular injection in the hippocampus of Tau368 mice. f DEPTAC decreased both soluble and insoluble tau in the hippocampus of Tau368 mice. g, h DEPTAC for a consecutive significantly reduced hippocampal phospho-tau and total tau (/ 10 μg total protein) after dox administration for 4 months (g), while the efficiency of DEPTAC on mouse tau was relatively limited in NW-administrated Tau368 mice (/ 30 μg total protein) (h). Unpaired t-tests, *p < 0.05, n = 3–4 mice in each group
